News

  • PLATTSBURGH, NY., September 30, 2014 – The Robarts Research Institute (Western University, London, ON) released a study demonstrating that, after 3 weeks of daily use, the Aerobika® device provides statistically significant outcomes in patients with Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis.  The study evaluated patients’ on Pulmonary Function Test, Six Minute Walk Test, the St. George’s Respiratory Questionnaire (SGRQ), the Patient Evaluation Questionnaire (PEQ) and Hyperpolarized Helium-3 Magnetic Resonance Lung Imaging (3He MRI).   Patients’ improvements included increased mucus clearance, decreased cough frequency and breathlessness, and enhanced exercise tolerance.  Additionally, the study revealed that patients reported an overall improvement in quality of life, without any adverse events reported while using the device.  

  • The Aerobika® Device, Marketed by Monaghan Medical in the United States, benefits COPD patients and wins Gold at MDEA Awards

    PLATTSBURGH, NY., July 16, 2014: The Aerobika® Oscillating Positive Expiratory Pressure (OPEP) Therapy System has earned Gold at the Medical Design Excellence Awards (MDEA). MDEA is an International Award recognizing groundbreaking products that save lives, improve patient healthcare, change the face of medical technology, and overcome design and engineering challenges. It is one of the medical technology industry's highest honors.

  • BACKGROUND: In vitro assessments of VHC performance are primarily designed to characterize aerosol formulations during product development and to ensure consistent product quality, rather than predict how the device will perform when used by a patient. In vivo, delivery is influenced by numerous factors, including device design, patient interface, patient compliance and airway anatomy. The use of casts of anatomical throats provides a means of reproducing the clinical situation more accurately. We report a
    laboratory-based comparison of aerosol drug delivery between two VHCs using a cascade impactor and a replica infant face and naso-pharyngeal airway developed from computed tomography (CT) scans. 

  • BACKGROUND: In order to improve patient compliance, the use of charge dissipative materials in VHC construction is becoming the standard of care. A facemask is required as the interface between patient and VHC for young children who cannot breathe through a mouthpiece. Recent studies have emphasized that a well-fitting facemask is critical for optimal drug delivery. We report a laboratory based comparison of aerosol drug delivery between two ‘antistatic’ VHCs under simulated breathing conditions, using a anatomically correct infant face-upper airway model (ADAM-III, Trudell Medical International (TMI)).

  • BPA exposure during late gestation accelerates secretory cell maturation in the proximal conducting airways. We identified a critical window of fetal susceptibility for BPA effects on lung epithelial cell maturation in the third trimester. This is of environmental health importance because increases in airway mucins are hallmarks of a number of childhood lung diseases that may be affected by BPA exposure.

  •  There is increasing interest in fully breath-actuated nebulizers (BANs) (1) because of the following
    reasons:

    1. The delivery of medication can be optimized by the near elimination of exhaled aerosol that would otherwise be wasted;
    2. The risk of contamination of the local environment by exhaled aerosol with consequent caregiver exposure is greatly reduced or eliminated altogether;
    3. There is the potential for dosimetric delivery.
  • Secretion mobilization by Oscillating Positive Expiratory Pressure (OPEP) is often given separately to inhaled medication

  • In the home-based situation, it can be helpful to be able to provide rapid bronchodilator therapy by nebulizer during exacerbations of obstructive lung disease

  • To date Oscillating Positive Expiratory Pressure (OPEP) therapy to mobilize secretions and reduce dyspnea has been routinely given at a separate time to inhaled medical aerosol therapy

  • AeroChamber Plus® Flow-Vu® AVHC Named A Top 10 Innovation in Technology by Allergy & Asthma Mothers of Asthmatics (AANMA)

    Top Ten Innovations in Technology Awards A panel of AANMA editors, board members, families, and volunteers recently took stock of the innovations and technologies that have changed our world. It was an interesting and challenging process made more difficult by trying to narrow it down to the top 10 within the last 25 years!

    AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (AVHC) Aerosol MDIs may have revolutionized inhalation therapy; however, there was a whole new problem – teaching people how to get the medicine inside their lungs!

    In 1983, AeroChamber Valved Holding Chamber (Monaghan Medical Corporation) would offer the answer. It could trap and hold or suspend medication particles long enough to be inhaled over a matter of moments rather than split seconds. Designed for use with any standard MDI, the clear devices were also easy to keep clean.

    In 2010, AeroChamber Plus® Flow-Vu® AVHC added the valve perched at the top of the device that moves only if the patient (child or adult) inhales deeply enough to empty the chamber. No more  guessing. The whole device is about the size of a baby bottle but lighter weight.